Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer

Lung Cancer ◽  
2009 ◽  
Vol 65 (3) ◽  
pp. 345-350 ◽  
Author(s):  
Armelle Lavolé ◽  
Christos Chouaïd ◽  
Laurence Baudrin ◽  
Marie Wislez ◽  
Gilles Raguin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Antiretroviral Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Highly Active Antiretroviral Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Highly Active

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

1986 ◽  
Vol 4 (4) ◽  
pp. 524-527 ◽  
Author(s):  
E Bork ◽  
M Hansen ◽  
P Dombernowsky ◽  
S W Hansen ◽  
A G Pedersen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Active Agent ◽  
Small Cell ◽  
Small Cell Lung ◽  
Phase Ii Trials ◽  
Highly Active

Teniposide, VM-26 (Vumon), was administered in a dose of 60 mg/m2 on days 1 to 5 every third week to 36 patients with histologically confirmed small-cell lung cancer. None had previously received chemotherapy or radiotherapy. The median age was 73 years (range, 52 to 79). Thirty-three patients were evaluable; 21 of these had local disease. Five patients had bone marrow metastases, four had liver involvement, and one CNS metastases. All patients had a performance status less than or equal to 2 before the start of treatment. Thirty patients obtained a response (90%), ten of whom had a complete remission (30%). The median duration of remission was 8+ months (range, 1.1 to 17+ months), whereas the median survival was 8.7 months (range, 1.9 to 20 months). Toxicity was primarily hematologic, with leukopenia the only dose-limiting effect. Besides alopecia, all other side effects were minimal including nausea and vomiting. We find these results provocative in regard to the response rate and the duration of response obtained as well as in reference to the dismal results that prior investigations in previously treated patients have shown. These data may indicate the need for reconsideration of the usual strategy for performing phase II trials.

Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non–Small-Cell Lung Cancer

2000 ◽  
Vol 18 (6) ◽  
pp. 1346-1350 ◽  
Author(s):  
Vincent A. Miller ◽  
Lee M. Krug ◽  
Kenneth K. Ng ◽  
Barbara Pizzo ◽  
Wendy Perez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Single Agent ◽  
Objective Response ◽  
Dose Intensity ◽  
Small Cell ◽  
Small Cell Lung ◽  
Highly Active

PURPOSE: Docetaxel and vinorelbine are active agents in advanced non–small-cell lung cancer (NSCLC) and demonstrate preclinical synergism perhaps, in part, through their inactivation of the proto-oncogene bcl-2. We show that docetaxel (60 mg/m2) and vinorelbine (45 mg/m2) can be safely combined when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed. PATIENTS AND METHODS: Thirty-five chemotherapy naïve patients with advanced NSCLC received vinorelbine as an intravenous push immediately followed by docetaxel as a 1-hour intravenous infusion once every 2 weeks. Prophylactic corticosteroids, ciprofloxacin, and filgrastim were used. RESULTS: We delivered median doses of 450 mg/m2 of vinorelbine and 600 mg/m2 of docetaxel. The major objective response rate was 51% (95% confidence interval [CI], 34% to 68%). With a median follow-up of 14 months, the predicted median survival time was 14 months, and the 1-year survival rate was 60% (95% CI, 44% to 80%). Febrile neutropenia occurred in five patients and five (1.3%) of 384 treatments. No dose-limiting neurotoxicity occurred. Symptomatic onycholysis and excessive lacrimation were observed after several months or more of therapy. CONCLUSION: Docetaxel 60 mg/m2 and vinorelbine 45 mg/m2, both given every 2 weeks, is a highly active combination for the treatment of advanced NSCLC. Filgrastim largely obviates neutropenic fever and allows for the single-agent dose-intensity of both drugs to be delivered. The occurrence of certain late toxicities can limit use in some cases and suggests that the combination could also be beneficial in settings requiring briefer, fixed periods of treatment, such as in induction or postoperative therapy.

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.

1997 ◽  
Vol 15 (1) ◽  
pp. 292-296 ◽  
Author(s):  
K Kubota ◽  
Y Nishiwaki ◽  
R Kakinuma ◽  
F Hojo ◽  
T Matsumoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Objective Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Weekly Chemotherapy ◽  
Thoracic Irradiation ◽  
Highly Active ◽  
Heavily Pretreated

PURPOSE This study was undertaken to determine the activity and toxicity of dose-intensive weekly chemotherapy (cisplatin, vincristine, doxorubicin, and etoposide [CODE] regimen) for previous treated, recurrent small-cell lung cancer (SCLC). PATIENTS AND METHODS The 17 patients with relapsed SCLC entered onto the study were to receive intensive weekly chemotherapy with the CODE regimen. All 17 patients had been heavily pretreated with some form of cisplatin-based combination chemotherapy. Six patients had received previous chemotherapy with CODE and one patient with cisplatin and etoposide (PE) as induction therapy. Nine patients had been treated with concurrent or sequential PE plus thoracic irradiation (TRT). The median time off chemotherapy was 6.7 months (range, 3.3 to 72). Patients were treated with 9 weeks of the CODE regimen. Response, survival, and toxicity data were noted. RESULTS All 17 patients were assessable for response, survival, and toxicity. Fifteen of 17 patients (88.2%) had an objective response, with five complete responses (CRs; 29%) and 10 partial responses (PRs; 58.8%). The median durations of response and survival were 156 days and 245 days, respectively. Myelosuppression was significant, with 76% of patients developing grade 4 leukopenia. No treatment-related death was observed. CONCLUSION The CODE regimen is highly active in the treatment of relapsed SCLC with an encouraging survival outcome.

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.

1991 ◽  
Vol 9 (9) ◽  
pp. 1627-1631 ◽  
Author(s):  
E Bork ◽  
J Ersbøll ◽  
P Dombernowsky ◽  
B Bergman ◽  
M Hansen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Randomized Study ◽  
Complete Response ◽  
Small Cell ◽  
Hematologic Toxicity ◽  
Small Cell Lung ◽  
Highly Active

A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity and toxicity of these two analogs in small-cell lung cancer (SCLC). Only previously untreated patients with SCLC were included; 46 and 48 patients receiving VP-16 and VM-26, respectively, are assessable for response. There were no differences between the two groups with respect to extent of disease, median age, and performance status (PS). The initial doses were for both compounds 70 mg/m2 intravenously (IV) daily for 5 days every 3 weeks. After inclusion of 25 patients in the study, the doses were increased to 80 mg/m2 for VM-26 and 90 mg/m2 for VP-16 because of differences in toxicity. VM-26 caused more hematologic toxicity than VP-16 throughout the study. The overall responses (complete response [CR] plus partial response [PR]) were 65% for VP-16 and 71% for VM-26, with CR occurring in 24% and 23%, respectively, for the two compounds. Median survival was 8.5 months for VP-16-treated patients versus 11.3 months for VM-26-treated patients (P = .58). It is concluded that both VP-16 and VM-26 are highly active single agents in SCLC.

Sign in / Sign up

Export Citation Format

Share Document